Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101)
Female Reproductive System Neoplasm
Explore 16 assets in Female Reproductive System Neoplasm →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
Liu Zi
Modality
gene_therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Indicative
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05051696CT.gov Intra-tumor Injection of Oncolytic Viruses H101 Combined With or Without Radiotherapy in Refractory/Recurrent Gynecological Malignancies | — | Active Not Recruiting | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Female Reproductive System Neoplasm
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) (this asset) | Liu Zi | P2 | CCC · 53 |
| Carboplatin | Wenjun Cheng | P3 | BB |
| Adriamycin | Amgen | P3 | BB |
| Peg-Rhg-Csf | Peking University | P4 | BB |
| Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]- | Sichuan Cancer Hospital and Research Institute | P3 | BB |
| Pembrolizumab | Sheba Medical Center | P2 | B |
| Erythropoietin | Amgen | P2 | B |
| Darbepoetin Alfa | Amgen | P2 | B |
| Nilotinib | National Cancer Institute (NCI) | P2 | B |
+21 more in the Female Reproductive System Neoplasm cohort
Other indications for Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101)
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Hepatocellular Carcinoma | — | P3 | B · 56 |
| Colorectal Cancer | — | P2 | CCC · 53 |
| Metastasis From Malignant Tumor Of Colon | — | P2 | CCC · 53 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
- CarboplatinWenjun ChengBB
- AdriamycinAmgenBB
- Peg-Rhg-CsfPeking UniversityBB
- Phosphonic Acid, P-[3-[[(2R,3R)-2-[(1R)-1-[3,5-Bis(Trifluoromethyl)Phenyl]Ethoxy]-3-(4-Fluorophenyl)-4-Morpholinyl]Methyl]-2,5-Dihydro-5-Oxo-1H-1,2,4-Triazol-1-Yl]-Sichuan Cancer Hospital and Research InstituteBB
- PembrolizumabSheba Medical CenterB
Citation
Floatz Terminal. Genetically-Modified Oncolytic Type 5 Adenovirus Which Selectively Replicates In Tumor Cells Containing Dysfunctional P53 Gene (H101) in Female Reproductive System Neoplasm. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/genetically-modified-oncolytic-type-5-adenovirus-which-selectively-replicates-in-tumor-cells-containing-dysfunctional-p53-gene-h101-female-reproductive-system-neoplasm
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →